According to SNS Insider, the U.S. Artificial Intelligence (AI) in Biotechnology Market was valued at USD 1.34 billion in 2025 and is expected to reach USD 6.98 billion by 2035, growing at a CAGR of 17.90% from 2026 to 2035. Globally, the market was valued at USD 3.91 billion in 2025 and is projected to reach USD 22.50 billion by 2035, expanding at a CAGR of 19.13% during 2026–2035. AI is revolutionizing the biotechnology sector through improved drug discovery, biological data analytics, precision medicine, biomarker detection, and better clinical trials. The availability of biological data sets, advances in machine learning and deep learning, and increased funding are accelerating AI incorporation. Pharmaceutical companies are using AI to minimize research and development costs, improve candidate selection, and decrease development time. The United States is the leading market due to considerable R&D expenditures, advanced healthcare infrastructure, and a healthy ecosystem of pharmaceutical, biotech, technology, and research firms. AI is used in drug discovery, molecular modeling, genomics, clinical data analytics, and precision medicine. NVIDIA Corporation is a top company, leveraging computing resources and AI-specific technologies. In 2025, NVIDIA, in collaboration with Eli Lilly, initiated an AI co-innovation laboratory worth a billion dollars to expedite discovery and clinical processes.